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Hereditary Inclusion Body Myopathy (HIBM) is a rare autosomal dominant or recessive
adult onset muscle disease which affects one to three individuals per million worldwide.
This disease is autosomal dominant or recessive and occurs in adulthood. Our previous
study reported a new subtype of HIBM linked to the susceptibility locus at 7q22.1-31.1.
The present study is aimed to identify the candidate gene responsible for the phenotype
in HIBM pedigree. After multipoint linkage analysis, we performed targeted capture
sequencing on 16 members and whole-exome sequencing (WES) on 5 members.
Bioinformatics filtering was performed to prioritize the candidate pathogenic gene
variants, which were further genotyped by Sanger sequencing. Our results showed that
the highest peak of LOD score (4.70) was on chromosome 7q22.1-31.1.We identified
2 and 22 candidates using targeted capture sequencing and WES respectively, only
one of which as CFTRc.1666A>G mutation was well cosegregated with the HIBM
phenotype. Using transcriptome analysis, we did not detect the differences of CFTR’s
mRNA expression in the proband compared with healthy members. Due to low incidence
of HIBM and there is no other pedigree to assess, mutation was detected in three
patients with duchenne muscular dystrophyn (DMD) and five patients with limb-girdle
muscular dystrophy (LGMD). And we found that the frequency of mutation detected in
DMD and LGMD patients was higher than that of being expected in normal population.
We suggested that the CFTRc.1666A>G may be a candidate marker which has strong
genetic linkage with the causative gene in the HIBM family.
Keywords: hereditary inclusion body myopathy, next-generation sequencing, CFTR, mutation, whole-exome
sequencing
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INTRODUCTION
Hereditary inclusion body myopathy (HIBM) refers to a rare
heterogeneous group of neuromuscular diseases with autosomal
recessive or dominant inheritance, which is characterized
by muscle fibers containing rimmed vacuoles and inclusions
consisting of tubulofilaments with a diameter of 15–21 nm
(Askanas and Engel, 1993, 1998; Broccolini and Mirabella,
2015). The most common form of HIBM, also known as
GNE myopathy, is autosomal recessive (Nonaka et al., 1981;
Nishino et al., 2002), and the other identified forms of HIBM
are autosomal dominant. This disorder of GNE myopathy is
mainly due to the UDP-Nacetylglucosamine 2-epimerase/N-
acetylmannosamine kinase (GNE) gene mutations, leading to
abnormal sialylation of glycoproteins and relentless muscle
degeneration (Argov and Yarom, 1984; Eisenberg et al., 2001).
A rare subtype is HIBM with Paget’s disease of the bone
and frontotemporal dementia (HIBM-PFD), which is due
to the valosin-containing protein (VCP) gene mutations,
resulting in abnormal accumulation of ubiquitinated proteins
and impaired autophagy in IBM-PFD muscle (Watts et al.,
2004; Ju et al., 2009; Nalbandian et al., 2011). Moreover,
autosomal dominant (AD) HIBM with congenital joint
contractures and external ophthalmoplegia is associated with
a mutation of the Myosin Heavy Chain IIa gene (MyHC-
IIa), which causes a pathogenic effect through interfering
with filament assembly or functional defects in ATPase
activity (Darin et al., 1998; Martinsson et al., 2000). Despite
advances in diagnosis and treatment, the heterogeneous
group of HIBM still remains clinically underrecognized.
Though a unique progression of muscle weakness with
HIBM, most patients go un-diagnosed due to lack of clinical
knowledge about this rare condition. In any case, early
diagnosis would understand disease progress and help avoid
unnecessary therapeutic options for these patients (Das et al.,
2016).
Therefore, much needs to be learned about the other forms
of HIBMs. Our previous study described a novel autosomal
dominant HIBM in a Chinese HIBM family of Han descent.
The clinical features of our family members are not compatible
with any known autosomal dominant or recessive HIBM.
With the exception of the mode of inheritance, the clinical
phenotype of this new form of IBM is similar to an atypical
adult onset HIBM2/DMRV which is characterized by muscle
weakness and atrophy beginning in the distal muscles of the
lower limbs with relative sparing of the quadriceps (Lu et al.,
2012). Further sequencing excluded the mutations in GNE gene.
Linkage analysis and haplotyping determined a new HIBM locus
on chromosome 7q22.1-31.1 (Lu et al., 2012). To identify the
corresponding causative gene defect in this muscle disorders, we
herein performed targeted capture sequencing and whole-exome
sequencing, and identified the c.1666A>G mutant in CFTR.
The CFTR c.1666A>G mutant was well co-segregate with the
HIBM phenotype in the verified members of the pedigree. After
further Sanger sequencing on 101 patients with muscle diseases,
the heterozygous c.1666A>G mutation in CFTR was identified
in 8 cases. Our results provided characteristic etiology for the
HIBM pedigree, and shed light on the corresponding pathogenic
mechanisms.
MATERIALS AND METHODS
Linkage Analysis
Our study was approved by the Institutional Ethics Committee
of Xuan Wu Hospital, the Capital Medical University, and the
written informed consents were obtained from all of the patients
involved. We firstly removed erroneous and uninformative
markers, then filtered markers if the distance of adjacent ones
smaller than 0.1 centimorgans (cM) (Lu et al., 2012). In
the present study, we performed multipoint linkage analysis
using SUPERLINK (V1.1) with parameters as follows: Mode
of inheritance, Dominant; multipoint window size, 3; Disease
mutant gene frequency, 0.1, 0.01, or 0.0001; penetrance, 0.8, 0.8
or 0.99, 0.99.
Targeted Capture and Whole-Exome
Sequencing
A SureSelect targeted capture kit for a genomic region (chr7:
100310001-130180000, hg19), which contained the susceptibility
locus was ordered from Agilent. DNA samples of 16 members of
HIBM pedigree were captured according to the manufacturer’s
specifications (Figure 1). Because the disease does not appear
until adulthood we did not include individuals from the pedigree
who were under 30 when we chose members of the HIBM
pedigree. Paired-end sequencing with 100-bp read length was
conducted on each sample using IlluminaHiSeq2000 system
(Illumina, San Diego, CA, USA). All paired reads were mapped
to the human reference genome (hg19) using BWA (version
0.7.15) (Li and Durbin, 2010). PCR duplicates of the reads were
removed using the Picard software program (version 1.92). The
GATK (McKenna et al., 2010) (version 3.6) and Pindel (Ye et al.,
2009) software packages were used to detect single nucleotide
variants and genomic structural variants, respectively. The cn.
MOPS package was used for copy number variation identifying
(Klambauer et al., 2012).
For whole-exome sequencing, the Agilent SureSelect Human
All Exon 50Mb kit was used to capture whole exomes of
5 members of the HIBM pedigree (Figure 1). The next-
generation sequencing assay and data analyzing were same as a
forementioned targeted capture sequencing.
Sanger Sequencing for Candidate Variants
of HIBM Pedigree
We designed the primer sets for the 2 mutations from
targeted capture sequencing and the 22 mutations from
whole-exome sequencing using Primer-Premier 5.0 (PREMIER
Biosoft International, Palo Alto, CA, USA). PCR reactions,
products purifying, and Sanger sequencing were performed
by ORI-GENE company. Sequence reads were analyzed using
Phred/Phrap/Polyphred/Consed (University of Washington,
Seattle, WA, USA) software and the genotype of variants were
manually confirmed.
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FIGURE 1 | The studied HIBM pedigree. The pedigree consists of 27 males (squares) and 32 females (circles), 15 affected (solid) and 20 unaffected (hollow)
members. Three deceased members (oblique line) of unknown phenotype and 21 members not old enough to determine phenotype (grayed squares and circles). The
genotype of CFTRc.1666A>G is labeled under collected samples. Purple triangles indicate members of pedigree used for whole exome sequencing and blue stars
indicate individuals used for targeted-capture sequencing.
Validating CFTRc.1666A>G in Sporadic
Patients With Muscular Dystrophy
Considering the lower incidence of HIBM, we have no way
to collect other pedigree of this new subtype of HIBM. So
we collected additional 101 patients with muscle diseases to
further verify the important roles of candidate variant in
muscle pathology. The peripheral blood was drawn from all the
individuals and genomic DNA was extracted. Using the primers
aforementioned, sequencing reaction was also performed by
ORI-GENE company and the frequency was further calculated.
RNA Extraction and Illumina
RNA-Sequencing
Total RNA was isolated from the skeletal muscle tissue from
patients III-1 and two healthy individuals from traffic injury
using the Trizol reagent (Invitrogen, CA, USA). The eligible
cDNA library was sequenced using the lluminaHiseq2000
platform by COMPASS biotechnology company. Differentially
expressed genes (DEGs) were identified with FDR<0.05. The
protein-protein interaction (PPI) network between CFTR and
DEGs was constructed using the information stored in BIOGRID
databases and visualized by Cytoscape software (Shannon et al.,
2003).
RESULTS
Susceptibility Locus Identified From
Linkage Analysis
Our previous linkage analysis has identified a locus on
chromosome 7q22.1-31.1 with a maximum multi-point LOD
score of 3.65 for the studied pedigree (Figure 1) using MERLIN
(Lu et al., 2012). However, limited by the computational
memory needed by MERLIN, some offspring were removed
from analyzing. Here, we employed a newly developed software
SUPERLINK-Online who can handle large pedigree by drawing
power from thousands of CPUs. Under the dominant inheritance
mode, a multipoint analysis implement on the pedigree
with several disease allele frequency and penetrance. We
again found that the highest peak of LOD score was on
chromosome 7q22.1-31.1, which was defined as a core region
that ranged from rs1617640 (chr7:100317048, hg19) to rs2966478
(chr7:112260976, hg19) (Figure 2A). The top SNPrs41261 has
the maximum LOD of 4.70 and 4.32 under penetrance of 0.99
and 0.8, respectively (Figure 2B). Frequency in the pedigree
= Number of patients/All tested samples∗2, Frequency in the
pedigree=23/37∗2=0.31081.
Identifying Causal Mutation Using
Next-Generation Sequencing
In order to pinpoint causal mutation, we carried out the targeted
capture sequencing on 16 samples from the HIBM pedigree
(Figure 3). Considering causal mutation maybe located in the
vicinity of the core region, we expanded the targeted region to
chr7:100310001-130180000 as a predesigned region. In order to
optimize the targeted region, we skipped the gene desert genomic
regions and large intergenic regions when designing the probes
for sequences outside the core region. In the end, the probes cover
about 5.86Mb genomic regions for the predesigned region.
Next-generation sequencing yielded an average coverage of
273.5X (standard deviation = 28.7) for the 5.86Mb genomic
region and identified 25,967 single-nucleotide variants (SNVs),
222 genomic structure variants (SVs), and 7 copy number
variation regions (CNVRs). After a process of variants filtering,
we finally obtained 2 candidates for the pedigree: c.1666A>G
(p.I556V) located in the exon 12 of CFTR, rs6960959 located
in a conserved region at the upstream of LEP(Leptin).We
genotyped the rest of collected family members and found only
c.1666A>G well segregated with HIBM in the pedigree. We
examined the c.1666A>G in SNP databases and found that the
global minor allele frequency is 0.0112 in 1000 Genomes project
(1KG) and CFTRc.1666A>Gwas not detected in the NHLBI
GO Exome Sequencing Project (about 6500 samples). The
candidate mutation of CFTRc.1666A>G was further evaluated
by investigating its prevalence in the public database curated
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FIGURE 2 | The multipoint parametric linkage scores of the studied pedigree.
(A) The LOD scores of markers from 92.8 to 117.7Mb on chromosome 7,
rs1617640:EPO, rs41261:CDHR3, rs2966478:LOC101928012. (B) The LOD
scores of rs41261 under the dominant inheritance mode with penetrance of
0.8, 0.8 or 0.99, 0.99 and mutant gene frequency of 0.1, 0.01, or 0.0001.
by the Genome Aggregation Database (gnomAD), which spans
123,136 exome sequences. The global minor allele frequency
of CFTRc.1666A>G is 0.003306 in the database of gnomAD.
Moreover, the allele frequency of CFTRc.1666A>G is 0.00291 in
ExAC.
Validating CFTRc.1666A>G Using
Whole-Exome Sequencing
In order to verify the CFTR c.1666A>G as a biomarker which
has strong linkage disequilibrium with the causative mutation
in the HIBM family, we performed whole-exome sequencing
on 5 individuals from the HIBM pedigree (Figure 1). A total
of 419,809 variants were identified from the whole-exome of 5
individuals and 22 variants were picked out as candidates after
a series of variants filtering, which contained the c.1666A>G
mutant in CFTR (Figure 3). After genotyping these 22 variants
in the HIBM pedigree, HNRPDLc.1332C>T was segregated well
with the 5 whole-exome sequencing individuals, while it was not
well segregated with the phenotype in our pedigree. Moreover,
we found that CFTRc.1666A>G mutant was the only one that
was well segregated with the phenotype.
The CFTR protein consists of five domains. There are two
transmembrane domains, each with six spans of alpha helices.
These are each connected to a nucleotide binding domain (NBD)
in the cytoplasm. The first NBD is connected to the second
transmembrane domain by a regulatory “R” domain that is a
unique feature of CFTR. The ion channel opens only when its
R-domain has been phosphorylated by PKA and ATP is bound at
the NBDs.We further performed the protein structure prediction
using the Protein Structure Prediction Server (PSIPRED). The
p.I556V is located in α-helical-rich conformation. The wild type
556I forms hydrogen bonds with the adjacent AA in the alpha-
helix domain. Similarly, the mutant 556V form hydrogen bonds
with the adjacent AA in the alpha-helix domain. However, the
free energy is much lower in mutant compared with wild type,
and the conformation seems more stable in mutant compared
with wild type.
CFTRc.1666A>G in Sporadic Patients With
Muscular Dystrophy
The results of linkage analysis, targeted-capture sequencing,
whole-exome sequencing and genotyping indicated that the
CFTRc.1666A>G is the most probable contributor to the HIBM
phenotype of this pedigree. We suggested that CFTRc.1666A>G
may be closely associated with muscle pathology and further
sanger sequencing on 101 patients with various muscle diseases
indicated that 8 cases are heterozygous for CFTRc.1666A>G
mutation and the mutation frequency was about 0.04, suggesting
the important roles of CFTRc.1666A>G in muscle pathology.
Of the 8 patients, three patients were with duchenne muscular
dystrophyn (DMD), which are characterized by progressive
muscle weakness, cardiomyopathy, and respiratory failure in
addition to cognitive impairment. The other five patients
were with limb-girdle muscular dystrophy (LGMD), typically
characterized by progressive weakness and wasting of the
shoulder and pelvic girdle muscles. Totally, the 8 patients shared
similarities of muscle weakness with the affected individuals of
HIBM family in clinical phenotype.
The Global Transcriptome Profiling of
HIBM
As in Table S1, 1651 differentially expressed genes (DEGs) in
total were identified in patients with HIBM compared with the
healthy individuals, including 1086 up-regulated DEGs and 565
down-regulated DEGs. MYH8 and FAM166B were the most
significant up-regulated and down-regulated DEGs, respectively.
MYH8 encodes myosin heavy chain 8 with ATPase activity
and act in filament binding, which functions in skeletal muscle
contraction. However, we found that the mRNA expression of
CFTR is not changed. The established PPI network showed that
11 differentially expressed genes interacted with CFTR. Among
these genes, GRN, CDH1, HSPA6, SLC9A3R1, B3GNT9, DCLK,
DAB2, and TMEM43 were up-regulated. GNB2L, NEDD4, and
TCEB2 were down-regulated as showed in Figure 4.
DISCUSSION
The HIBMs are composed of a group of rare muscle disorders
with different etiologies and clinical presentations (Askanas
Frontiers in Neuroscience | www.frontiersin.org 4 May 2018 | Volume 12 | Article 329
Lu et al. CFTR c.1666A>G Mutation in HIBM
FIGURE 3 | The flow chart of variants filtering. N, the number of variants; HIBM, hereditary inclusion body myopathy; phastCons score, base-by-base conservation
score; GERP score, Genomic Evolutionary Rate Profiling score for producing position-specific estimates of evolutionary constraint; HapMap, the international
haplotype map project; ESP, the NHLBI GO Exome Sequencing Project; ExAC, The Exome Aggregation Consortium. a. Variants are called without limited by the
targeted regions.
and Engel, 1993). There are mainly five different HIBMs,
such as HIBM1, HIBM2, HIBM-PFD, HIBM-ERF, and HIBM3.
Numerous studies have been performed and a few causal
mutations had been reported (Nonaka et al., 1981; Horowitz
and Schmalbruch, 1994; Darin et al., 1998; Goldfarb et al.,
1998; Martinsson et al., 1999, 2000; Saavedra-Matiz et al., 2000;
Nishino et al., 2002). Besides, our previous study described a
new subtype of HIBM named as HIBM4. A novel susceptibility
region was identified, which was located on chromosome 7q22.1-
31.1 (Lu et al., 2012). Considering that gene mutations are the
pathological basis of HIBM, we identified the candidate CFTR
gene responsible for the phenotype in HIBM family by using
targeted capture sequencing and whole-exome sequencing to
elucidate the specific pathogenic mechanism and therapeutic
perspectives of this novel subtype of HIBM.
Further linkage studies by SUPERLINK-Online software
showed the same results as previous, suggesting that the
susceptibility locus was located at 7q22.1-31.1. According to the
prediction results of CFTR protein, we speculated that p.I556V
in the CFTR may affect the channel from functioning properly,
leading to a blockage of the movement of salt and water into
or out of cells. To further verify whether the CFTR is causative
gene, we performed targeted capture sequencing on 16 subjects
and whole-exome sequencing on 5 individuals, indicating that
CFTRc.1666A>G (p.I556V) was well segregated with HIBM in
the verified pedigree. Moreover, the CFTRc.1666A>G mutation
was also detected in 8 of the 101 patients with muscle diseases.
But we did not detect the change in the expression level of CFTR
after RNA-seq. There is no sufficient evidence to conclude that
CFTR is causative gene, we hypothesized that CFTR mutation is
a marker with strong linkage disequilibrium with the causative
gene for HIBM4. We also established PPI network based on
CFTR and found 11 DEGs among them. The 11 DEGs have no
relationship with HIBM after retrieve.
In order to explore the causative gene that is linked to the
CFTR, we retrieved the function of 40 genes in the upstream and
downstream of the CFTR gene within 10Mb. Interestingly, two
of them as Interferon related developmental regulator 1(IFRD1)
and Protein phosphatase 1 regulatory subunit 3A (PPP1R3A)
were deserved to be mentioned. IFRD1 is an immediate early
gene that encodes a protein related to interferon-gamma (Buanne
et al., 1998). Mutations in this gene are related to sensory/motor
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FIGURE 4 | PPI network of CFTR and DEGs in HIBM. The up-regulated DEGs are in red and those down-regulated are in green.
neuropathy with ataxia. This gene may also be involved in
modulating the pathogenesis of cystic fibrosis1. A previous study
reported a single missense variant c.514 A>G in IFRD1 gene that
was associated with Spinocerebellar ataxias (SCA18), which is
an autosomal dominant sensory/motor neuropathy with ataxia.
Symptoms included features of motor and sensory neuropathy,
ataxia, pyramidal tract signs, dysmetria, and muscle weakness
(Lin et al., 2018). However, the RNA-seq results showed no
significant change of IFRD1 expression in skeletal muscle tissue
of patients with HIBM4 compared with normal control.
PPP1R3A and the glycogen-associated form of protein
phosphatase-1 (PP1) derived from skeletal muscle is a
heterodimer composed of a 37-kD catalytic subunit and a
124-kD targeting and regulatory subunit. This gene encodes
the regulatory subunit which binds to muscle glycogen with
high affinity, thereby enhancing dephosphorylation of glycogen-
bound substrates for PP1 such as glycogen synthase and glycogen
phosphorylase kinase (Montori-Grau et al., 2007). Stored
glycogen is an important source of energy for skeletal muscle. It
is well known that human genetic disorders primarily affecting
skeletal muscle glycogen turnover. Savage et al. (2008) identified
a PPP1R3A FS (frameshift (FS) premature stop mutation in
PPP1R3A (C1984DAG; stop codon 668; referred to subsequently
asPPP1R3A FS variant), which encodes a truncated protein
that is mistargeted within the cell. This mutation decreases
1IFRD1 interferon-related developmental regulator 1 [Homo sapiens (human)][J].
muscle glycogen synthase activity, thereby decreasing muscle
glycogen content in humans and mice (Savage et al., 2008).
In the present study, we found that PPP1R3A was located at
chromosome7q22.1-31.1. Moreover, PPP1R3A was significantly
differentially expressed in skeletal muscle tissue of patients with
HIBM4 compared with normal control. So we speculated that
PPP1R3A may be closely related to the pathogenesis of HIBM4.
Taken together, our exome trapping studies suggested that the
CFTRc.1666A>G may be a candidate marker which has strong
linkage disequilibrium with the causative gene in the HIBM4
family. By scanning the upstream and downstream regions of
the CFTR gene, we found that PPP1R3A was closely related
to the HIBM. Therefore, we speculated that PPP1R3A may be
the potential candidate causative gene for the HIBM4 pedigree.
Our results will be helpful to better understand the molecular
mechanisms and the pathogenesis of HIBM4.
Even so, our study has some limitations. Unfortunately we
were not able to identify mutations in PPP1R3A by re-analyzing
the data of targeted sequencing and WES, which is mainly due
to the deficiency of capture technology in deep (next-generation)
sequencing technologies, including the coverage of different
exome databases, target coverage efficiency, GC bias, sensitivity
in single nucleotide variant detection, etc. In future study, the
genomic DNA will be extracted and the entire coding region and
the intron-exon boundaries of PPP1R3A gene will be sequenced
to confirm whether PPP1R3A might be the gene responsible for
HIBM4 pedigree.
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